scholarly journals A review of pharmacogenetic aspects of methotrexate and 6-mercaptopurine toxicity in pediatric acute lymphoblastic leukemia treatment

2021 ◽  
Vol 8 (3) ◽  
pp. 79-85
Author(s):  
О. D. Gurieva ◽  
М. I. Savelyeva ◽  
Т. Т. Valiev
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Side Effects ◽  
Supportive Care ◽  
Lymphoblastic Leukemia ◽  
Molecular Profiling ◽  
Significant Progress ◽  
Pediatric Acute Lymphoblastic Leukemia ◽  
Leukemia Treatment ◽  
Risk Of Relapse

Significant progress in the treatment of acute lymphoblastic leukemia (ALL) in children has resulted from the development of effective chemoand supportive care therapy protocols. The vector of further research is aimed at reducing toxicity and long-term side effects. The study of pharmacogenetic aspects of toxicity of the main drugs used in the treatment of ALL – methotrexate and 6-mercaptopurine – allowed to identify oligonucleotide polymorphisms that correlate with the concentration of the drug in blood, toxic effects and the risk of relapse of ALL. The clinical administration of pharmacogenetic methods remains a challenging task, requiring additional research, which will make it possible to individualize the ALL therapy on the basis of the results of molecular profiling.

Pediatric Acute Lymphoblastic Leukemia: Is There Still a Role for Transplant?

Hematology ◽  
2010 ◽  
Vol 2010 (1) ◽  
pp. 363-367 ◽  
Author(s):  
Stella M. Davies ◽  
Parinda A. Mehta
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Side Effects ◽  
Lymphoblastic Leukemia ◽  
Significant Progress ◽  
Pediatric Leukemia ◽  
Improve Outcome ◽  
Pediatric Acute Lymphoblastic Leukemia ◽  
Rigorous Approach ◽  
Biological Studies ◽  
Late Side

Abstract Constant questioning of the applicability of transplant for any diagnosis is appropriate. This is particularly necessary in fields such as pediatric leukemia, in which significant progress in therapy and risk classification is being made. Outcomes with chemotherapy are constantly improving, and donor availability and transplant outcomes are also better. It is important to be aware of likely outcomes when counseling families and recommending therapy, and to consider issues of likely late side effects. Biological studies that predict prognosis, for example, array-based studies, hold hope of identifying the children destined to relapse at the outset of disease. However, a rigorous approach must be taken in determining whether transplant does improve outcome whenever this strategy is applied.

Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy

Hematology ◽  
2013 ◽  
Vol 2013 (1) ◽  
pp. 126-130 ◽  
Author(s):  
Mary V. Relling ◽  
Laura B. Ramsey
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Genomic Variation ◽  
Whole Genome ◽  
Lymphoid Leukemia ◽  
Interindividual Differences ◽  
Genomic Variants ◽  
Short And Long Term ◽  
Risk Of Relapse

Abstract Childhood acute lymphoblastic leukemia (ALL) provides an outstanding model for pharmacogenomic research: it is a drug-responsive disseminated cancer that is cured with medications alone in ∼ 85% of patients, but relapse remains unacceptably high for some subgroups. Inherited genomic variation contributes to the risk of relapse and to the risk of short- and long-term serious adverse effects of therapy. Our goal is to identify the inherited genomic variants that contribute to interindividual differences in response in patients with ALL. We discuss results of whole-genome interrogations of germline DNA in ALL.

Long-term survivors of acute lymphoblastic leukemia — risk of relapse after cessation of therapy

1981 ◽  
Vol 9 (3) ◽  
pp. 209-218 ◽  
Author(s):  
Yaddanapudi Ravindranath ◽  
Dushyant T. Soorya ◽  
Gary E. Schultz ◽  
Jeanne M. Lusher
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Long Term Survivors ◽  
Risk Of Relapse

Predicting the neurobehavioral side effects of dexamethasone in pediatric acute lymphoblastic leukemia

2016 ◽  
Vol 72 ◽  
pp. 190-195 ◽  
Author(s):  
Lidewij T. Warris ◽  
Erica L.T. van den Akker ◽  
Femke K. Aarsen ◽  
Marc B. Bierings ◽  
Cor van den Bos ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Side Effects ◽  
Lymphoblastic Leukemia ◽  
Pediatric Acute Lymphoblastic Leukemia

scholarly journals Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia

Hematology ◽  
2017 ◽  
Vol 2017 (1) ◽  
pp. 259-264 ◽  
Author(s):  
Lewis B. Silverman
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Kinase Inhibitors ◽  
Lymphoblastic Leukemia ◽  
High Risk Patient ◽  
Newly Diagnosed ◽  
Pediatric Acute Lymphoblastic Leukemia ◽  
Novel Treatments ◽  
Relapsed Disease ◽  
Multiagent Chemotherapy

AbstractWith current available therapies, the prognosis for most children and adolescents with acute lymphoblastic leukemia (ALL) is favorable. However, the multiagent chemotherapy regimens used to treat newly diagnosed patients are associated with many acute and long-term complications, and therapy for relapsed disease is intensive and suboptimally effective. Over the last decade, several nonchemotherapeutic approaches have been evaluated, with the goal of identifying more effective, less toxic therapies that can be used in conjunction with, or even replace, current regimens. Novel nonchemotherapeutic therapies with activity in ALL include (1) tyrosine kinase inhibitors in high-risk patient subsets in whom potentially targetable alterations have been identified and (2) immunotherapeutic approaches, such as monoclonal antibodies, immunotoxins, bispecific T-cell–engaging antibodies, and chimeric antigen receptor T cells. This review summarizes promising results from recent clinical trials of these novel treatments.

Sign in / Sign up

Export Citation Format

Share Document